Company ProfilePremium

Austco Healthcare Limited

Company Profile Analysis

Ticker: AHC.AX

ESOMAR 23 Corporate BadgeISO Certifications Badge
Austco Healthcare Limited - Company showcase

Year Founded & Workforce

1986

271 Employees

Austco Healthcare Limited logo

Austco Healthcare Limited Employee Contacts

We don't hold contact details for this company yet — you can request them.

Request Employee Contacts

Austco Healthcare Limited Overview

Austco Healthcare is a Melbourne-headquartered, ASX-listed micro-cap that designs, manufactures, installs and maintains clinical communications systems — principally nurse call, mobile clinical messaging, clinical workflow, real-time location services (RTLS) and enterprise reporting — for hospitals and aged-care facilities. Its proprietary Tacera IP nurse call platform, supported by the Medicom range and the Pulse software suite (Pulse Mobile, Pulse Insights, Pulse Manage), sits at the bedside-to-command-centre layer of a facility's digital infrastructure. With FY26 revenue of A$94.2m, EBITDA of A$14.9m and NPAT of A$9.0m, Austco is a small but profitable, debt-free specialist competing against much larger diversified medtech and communications vendors. Since 2023 it has executed a disciplined "buy-your-reseller" roll-up (Teknocorp, Amentco, G&S Technologies, Medical Communications Systems) at a consistent 3.5x normalised EBITDA, converting channel partners into direct sales and installation capability, while seeking to lift the share of higher-margin software and maintenance revenue from an installed base of more than 5,000 facilities.


Company's own description

In its FY26 Directors' Report, Austco describes its principal activities as (i) development of software and manufacture of hardware relating to healthcare and electronic communications systems; (ii) global marketing and sales of electronic healthcare communication systems to established and new customers; and (iii) installation of its own developed and manufactured electronic healthcare communication systems together with third-party sourced complementary low-voltage systems, including access control and security systems (FY26 Appendix 4E, Directors' Report, "Principal Activities"). The company styles itself a "global leader in clinical communications solutions" in its results releases.

The FY26 Investor Presentation frames the portfolio as spanning communication (Tacera and Medicom), workflow optimisation (Pulse Mobile), real-time location services and enterprise reporting, installed together with surrounding low-voltage infrastructure. It maps its role in a facility in four layers: the bedside (call points, in-room devices, RTLS components), the ward (alerts, notifications, mobile applications, touchscreens and displays routing calls to the right clinician), facility-wide software (Tacera handling alarm management, call routing, audio communications and third-party clinical system data) and the command centre (enterprise reporting, operational insight, system readiness monitoring and fall detection).

Business model

Management describes a three-stage model: bid and win, install, and service and extend (FY26 Investor Presentation, "The Austco Healthcare business model"). Clinical communications is typically specified into a building at design stage — often years before construction — and tendered as part of the build programme. An award enters Unfilled Contracted Revenue (UCR) at signing and converts to revenue as equipment is delivered and installation is completed, with a software maintenance agreement (SMA) following commissioning. Once installed, a system's life is measured in decades, giving Austco an annuity opportunity for software upgrades, maintenance and additional modules from a customer already won.

Revenue model

Revenue line (FY26)AUD Mn% of groupYoY growthRecognition basisSource
Equipment51.955%+12.1%Point in time, on transfer of controlFY26 Note 2(b); Investor Presentation
Installation31.033%+21.4%Over time, as performance obligation satisfiedFY26 Note 2(b)
Software & SMA11.412%+19%Perpetual licences at point of sale (A$5.1m); SMAs and term licences over 1–5 year term (A$6.3m)FY26 Note 2(b); Directors' Report
Total94.2100%+15.8%——

The model is therefore predominantly product and project-based (88% equipment plus installation), with a recurring layer (SMA and term licences) of roughly 6.7% of revenue recognised over time and a perpetual-licence software layer of roughly 5.4%. There is no material subscription/SaaS revenue disclosed separately; licensing is primarily perpetual.

Value-chain position

Austco is vertically integrated across design (US software development centre and Australian engineering), hardware manufacture (via contract and own assembly — the company references "alternative assembly and distribution models" in its supply-chain risk disclosure), go-to-market (direct in six countries, plus a global network of certified resellers and partners), installation (now substantially in-house in Australia and New Zealand following the four reseller acquisitions) and lifecycle maintenance. The North America segment acts as the product and development hub, recording A$13.0m of intersegment sales to other regions in FY26 (FY26 Note 5).

Customer types and end-markets

Customers are public and private acute hospitals, community hospitals, long-term care and residential aged-care operators, and mental health and rehabilitation facilities. Named reference customers disclosed in FY25–FY26 include Ng Teng Fong General Hospital and Jurong Community Hospital (Singapore), Hospital Israelita Albert Einstein (São Paulo, Brazil), Warrnambool Base Hospital (Victoria), North York General Hospital long-term care (Canada), Toronto Western Hospital (Canada), Angeles Health (Mexico) and the company's unnamed "largest US customer", which is rolling out Pulse Mobile across about 180 hospitals.

Independent characterisation

Austco is best understood as a niche hardware-plus-software clinical communications OEM that is converting itself into a vertically integrated systems integrator in Australasia, while remaining a channel-led OEM in North America, Asia, Europe and Latin America. Its economic engine is the project tender; its strategic prize is the installed base. The acquisitions have lifted revenue but also raised the proportion of lower-margin installation work and third-party low-voltage systems, so headline growth has outpaced the growth of the software layer. The investment case rests on whether the company can (a) keep winning projects in a market dominated by much larger players, (b) monetise its base through SMAs (the July 2026 ten-year Jurong SMA is the template) and Pulse software, and (c) extract operating leverage as acquired cost bases annualise.

Strategy

Stated strategy themes (FY26 Investor Presentation, "Strategy and outlook")

Management articulates five priorities, paraphrased:

  1. Continuous innovation — A$4.8m invested in the Tacera platform in FY26, with an AI roadmap extending across predictive care, workflow and system health.

  2. Expand recurring revenue — software and maintenance up 19% to A$11.4m (12.0% of revenue), anchored by the ten-year, A$4.2m Jurong SMA.

  3. Enhance margin profile — gross margin up 140bp to 53.4% via integration-driven supply-chain efficiencies; operating leverage expected as acquired cost bases annualise.

  4. Disciplined and selective M&A — four reseller acquisitions in three years at conservative multiples, each with a performance-based earn-out.

  5. Deepen market presence — flagship reference sites in every region (Einstein in Latin America, Jurong in Asia, national ANZ coverage).

The 2025 AGM presentation framed Austco as positioned to target 10–14% organic revenue growth, supported by healthcare megatrends (ageing populations, healthcare digitalisation, regulatory and compliance demands, workforce shortages).

Initiatives announced in the last 24 months

DateInitiativeCategoryDetail / targetSource
Apr–May 2025Acquisition of G&S TechnologiesInorganic growth / direct salesNZ$22.9m revenue, NZ$2.9m EBITDA; 3.5x EBITDAASX term sheet (9 Apr 2025)
1 Apr 2025Largest SMA contract in company historyRecurring revenue—Halo announcement feed
FY26Integration programme across Teknocorp, Amentco, G&SCost / marginSupply-chain efficiencies; gross margin to 53.4%FY26 Directors' Report
FY26Tariff mitigation strategyCost / riskSourcing, country of origin and pricing reviewFY26 Material Business Risks
FY26Cyber uplift to ACSC Essential EightRisk / governanceUnderway, with penetration testingFY26 Material Business Risks
Jun 2026Pulse Mobile US rolloutPlatform / recurring~180 hospitals of largest US customer during calendar 2026FY26 Trading Update
Jul 2026Ten-year Jurong SMARecurring revenueA$4.2m, 1 Oct 2026–30 Sep 2036ASX (24 Jul 2026)
Aug 2026MCS acquisitionInorganic growth+A$1.88m net revenue, +A$0.82m EBITDA (FY basis)ASX (10 Aug 2026)
Aug 2026AI roadmapInnovationPredictive intelligence, workflow optimisation, analytics, predictive maintenanceFY26 Investor Presentation
FY27Formal succession planning programmeGovernanceEndorsed by Nomination & Remuneration CommitteeFY26 Directors' Report

ESG/sustainability commitments

No emissions targets, net-zero commitments or sustainability-linked financing have been disclosed. The company states its operations are not significantly affected by Australian environmental regulation (FY26 Directors' Report).

Medium-term targets and guidance

ItemGuidanceOutcomeSource
FY26 organic revenue growth10–14% (Oct 2025)Not separately reported; total growth 15.8% including G&S annualisationQ1 FY26 Trading Update
FY26 revenueA$90–95m (Jun 2026)A$94.2m (top half)FY26 Trading Update; Appendix 4E
FY26 EBITDAA$14.0–14.6m (Jun 2026)A$14.8m (above range)As above
FY26 NPATA$9.0–9.4mA$9.0m (bottom of range)As above
FY26 gross margin~52.8%53.4%As above
FY26 EBITDA margin~15.5%15.8%As above
FY27No quantitative guidance; "healthy sales pipeline, momentum across all regions" and A$51.2m UCR—FY26 Investor Presentation

Products & Services

Austco does not disclose product-level revenue or pricing. The catalogue below is compiled from the FY26 Investor Presentation, ASX releases and company descriptions reproduced by data providers. Products are sold across all geographic segments.

Nurse call and clinical communications platforms

ProductDescription and capabilitiesTarget customerLaunch / latestPricingFlagship references
TaceraInternet-protocol nurse call and clinical communications platform; every component IP-configurable with its own address, enabling system supervision; handles alarm management, call routing, audio communications and integration of information from third-party clinical systemsAcute hospitals, large aged careDeveloped late 2000s; commercially deployed by c. 2011–12 (Fiona Stanley, Canberra Hospital, HealthSouth); continuously developed (A$4.8m invested in FY26)Project-priced; perpetual software licence plus SMA; not disclosedNg Teng Fong GH & Jurong CH (Singapore); Hospital Israelita Albert Einstein (Brazil); Warrnambool Base Hospital (VIC)
Tacera hardware familyPendants, pillow speakers, patient call points, pull cords, bathroom call points, annunciators, over-door lights, touchscreen nurse stations, audio devices, in-room devicesAs aboveOngoingPer-device, project-pricedEinstein retrofit: 550 patient stations, 560 over-door lights, >1,000 bathroom call points, 33 nurse stations/annunciators
MedicomLower-cost nurse call system positioned as a cost-effective alternative to TaceraAged care, smaller facilities, budget-constrained buyers———

Mobile, workflow and analytics software (Pulse suite)

ProductDescription and capabilitiesTarget customerLaunch / latestPricingNotes
Pulse MobileNative iOS/Android application allowing clinical staff to receive and manage nurse call alarms on the move and trigger workflows remotelyHospitals seeking clinical mobilityNot disclosed; major US deployment during calendar 2026Licence plus SMA; not disclosedContracted rollout across ~180 hospitals of largest US customer (FY26 Trading Update)
Pulse InsightsEnterprise analytics: response-time analysis, staffing adequacy and compliance-readiness dashboards; foundation for AI-informed analysis of call volume and staffing, unusual call patterns and automatic workflow assignmentHospital administrators, aged-care operatorsLive (FY26)—Named in FY26 AI roadmap
Pulse ManageManagement and administration module within the Pulse suite (functional detail not separately disclosed)Facility managersLive (FY26)—Named in FY26 enterprise products slide
Pulse Reports / Enterprise ReportingEnterprise reporting and analytics platform across sitesMulti-site operators——Described by data providers
Clinical WorkflowEnables staff to communicate with ancillary departments, measure adherence to protocol and control other systemsHospitals———
System Readiness monitoringMonitors network, servers, device faults and database storage to assure system availabilityAll installed sitesLive (FY26)Typically bundled with SMA (not disclosed)Supports SMA value proposition

Location, safety and sensing

ProductDescriptionTarget customerStatus
Built-in RTLSReal-time location services embedded in the nurse call platform, identifying who is calling and where; staff and patient location componentsHospitals, aged careLive
Fall detection and movementRadar- or camera-based detection intended, over time, to anticipate resident needs rather than only respondAged care, mental healthLive/roll-out (FY26 Presentation)

Services

ServiceDescriptionRevenue line
Installation and integrationConfiguration and integration of Austco systems and surrounding low-voltage infrastructure; integration with third-party clinical systemsInstallation (A$31.0m FY26)
Low-voltage and security systemsThird-party access control, security and related systems installed by acquired integrators (Teknocorp, Amentco, G&S, MCS)Equipment and installation
Software Maintenance AgreementsOne- to five-year maintenance agreements (now including a ten-year SMA at Jurong)Software & SMA
WarrantyOne- to five-year product warranties (provision A$0.32m at 30 Jun 2026)Cost provision

AI roadmap (announced, not yet separately monetised)

The FY26 Investor Presentation sets out four AI layers across Tacera, Pulse and RTLS: (1) predictive clinical intelligence — fall-risk scoring, call-anomaly detection and deterioration early warning from call data and RTLS positioning; (2) intelligent workflow optimisation — AI-based staff routing by acuity, workload, proximity and skill; (3) operational analytics and decision support — foundations live in Pulse Insights; (4) predictive maintenance and system health — AI monitoring of installed hardware to flag device issues before downtime. No launch dates, pricing or revenue targets were disclosed.

Financial Narrative

All figures A$m unless stated; fiscal years ending 30 June. Sources: FY26 Appendix 4E (including five-year performance table in the Remuneration Report); FY25 Results Media Release; FY23 and FY22 Results Releases.

Income statement — five-year

FY22 software/SMA derived from 14.4% of A$35.9m; FY23 from 20.2% of A$42.0m (FY23 Results Release). FY24 share (16.0%) analyst-calculated. Revenue CAGR FY22–FY26: 27.3%; NPAT CAGR FY22–FY26: 40.2% (analyst-calculated).

Source conflict: An InvestSMART AI-generated summary attached to the FY23 annual report link cites FY23 revenue of A$40.9m, a 30.5% increase and NPAT of A$3.2m. These figures conflict with the company's own FY23 release (A$42.0m, +17%, NPAT A$2.26m) and with the five-year table in the FY26 Remuneration Report (A$41.978m, NPAT A$2.258m). The primary-source figures are used.

Income statement — three-year detail

Sources: FY26 Appendix 4E; FY25 Results Release (FY24 gross profit derived as FY25 gross profit A$42.4m less A$11.7m increase). FY23 NPBT was A$1.8m (FY25 Results Release). Note: the company reports FY26 EBITDA as A$14.849m, rounded to A$14.9m in commentary.

Commentary — growth and margins. Revenue nearly tripled between FY22 and FY26. The inflection came in FY24–FY25, driven by acquisitions: Teknocorp (completed November 2023) contributed about A$6.5m and Amentco (May 2024) about A$2.7m in FY24 according to an independent analyst reconciliation, while FY25 benefited from full-year Amentco and one month of G&S. Organic growth in FY25 was roughly 17% (about A$7m), concentrated in North America and Asia (Strawman analyst summary of the FY25 result — secondary source). FY26 growth of 15.8% was more balanced, but the half-year split is critical: 1H26 grew 30.7% while 2H26 grew only 3.4% to A$46.0m, reflecting lumpy project timing, slower construction programmes and tighter hospital capital budgeting.

Gross margin has been remarkably stable in a 52–53.5% band despite a mix shift towards installation; the FY26 improvement to 53.4% came from lower absolute material costs, supply-chain efficiencies through integration and tariff mitigation. EBITDA margin expanded from 13.8% (FY24) to 16.0% (FY25) then eased slightly to 15.8% as overheads grew 22–24% — faster than revenue — with a full year of G&S costs and investment in people. Overheads rose to 42.4% of revenue in FY26 from 40.0% in FY25.

Commentary — earnings quality. Statutory NPAT is noisy. FY24 was flattered by a A$1.4m tax credit on recognition of tax assets; FY25 was depressed by a non-deductible A$2.2m contingent consideration expense (Amentco earn-out outperformance); FY26 was flattered by a non-assessable A$0.9m benefit from a downward revision to the G&S earn-out. On management's underlying basis, NPAT was flat at A$8.1m in both FY25 and FY26 — the single most important nuance for investors and a key reason the share price fell after the June 2026 trading update despite the headline 52% NPAT increase.

Balance sheet

Sources: FY26 Statement of Financial Position and Statement of Changes in Equity (FY24 equity = opening balance at 1 July 2024; FY24 cash = opening cash in FY25 cash-flow statement). FY26 goodwill unchanged because MCS completed after balance date.

Commentary. Austco has no bank debt; "short-term borrowings" of A$0.14m are immaterial. The main quasi-debt items are leases (A$3.8m) and contingent consideration, which fell from A$12.8m to A$2.5m after the A$6.0m cash settlement of the Amentco earn-out (part of which appears to have been settled in shares — contributed equity rose A$3.59m in FY26 with negligible cash proceeds) and the downward revision of the G&S earn-out. The remaining G&S earn-out of A$2.5m is due in March 2027; the MCS earn-out (estimated A$0.64m) is payable after the FY27 audit. Goodwill and intangibles (A$28.2m) represent 45% of equity, typical for a roll-up. Contract liabilities (customer prepayments) fell from A$6.4m to A$3.8m, a modest working-capital headwind and consistent with fewer up-front billings on new projects in 2H26.

Cash flow

Source: FY26 Consolidated Statement of Cash Flows; FCF and conversion analyst-calculated.

Commentary. Cash generation is solid and has funded four acquisitions without debt or a cash equity raise. FY26 cash conversion fell to 84% of EBITDA as inventory rose A$2.0m and contract liabilities unwound, partly offset by lower receivables. 1H26 operating cash flow of A$9.2m effectively matched 1H EBITDA of A$8.3m (1H26 release), implying a weaker 2H26 cash performance.

Ratios

All ratios analyst-calculated from FY26 statements. ROIC uses EBIT x (1 – 22.3% effective tax) over equity plus borrowings plus leases less cash at 30 Jun 2026. Working-capital days use year-end balances against revenue (DSO) and materials & direct labour (DIO, DPO); payables include all trade and other payables, so DPO is overstated relative to pure trade creditors. Negative net debt/EBITDA indicates net cash.

Commentary. Returns are healthy for an industrial technology micro-cap and improving, aided by acquisitions bought at low multiples (3.5x EBITDA implies a pre-tax return on purchase price above 25% before integration costs). Liquidity improved markedly in FY26 as the Amentco earn-out was paid and current contingent liabilities fell. Working capital is the main capital consumer: the business must carry inventory for long-cycle projects and extend credit to public health customers.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Financial Detail

Income Statement and Margin Analysis (%)

MetricFY2022FY2023FY2024FY2025FY2026

Revenue from customers (AUD Mn)

35.942.058.281.494.2

Revenue growth (%)

1517394015.8

Software & SMA revenue (AUD Mn)

5.28.59.39.611.4

Software & SMA share of revenue (%)

14.420.216.011.712.0

Net profit after tax (AUD Mn)

2.332.267.085.939.01

Net margin (%)

6.55.412.27.39.6

Basic EPS (A cents)

0.820.782.331.632.41

Dividends paid per share (A cents)

00.475000

Year-end share price (AUD)

0.100.170.180.290.25

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Income Statement and Margin Analysis (%) (FY2024–FY2026)

MetricFY2024FY2025FY2026

Revenue (AUD Mn)

58.281.494.2

Gross profit (AUD Mn)

30.742.450.3

Gross margin (%)

52.852.053.4

Overhead cost base excl. D&A (AUD Mn)

25.032.639.9

EBITDA (AUD Mn)

8.113.014.8

EBITDA margin (%)

13.816.015.8

Depreciation & amortisation (AUD Mn)

—2.94.0

EBIT (AUD Mn)

—10.210.9

Contingent consideration (expense)/benefit (AUD Mn)

0-2.20.9

Profit before tax (AUD Mn)

5.78.111.6

Income tax expense (AUD Mn)

—2.12.6

Effective tax rate (%)

not meaningful (A$1.4m tax credit)

26.422.3

NPAT (AUD Mn)

7.15.99.0

Underlying NPBT excl. contingent consideration (AUD Mn)

—10.310.7

Underlying NPAT excl. contingent consideration (AUD Mn)

—8.18.1

Diluted EPS (A cents)

—1.602.38

“—” = not publicly disclosed.

Balance Sheet and Per-Share Data

MetricFY2024FY2025FY2026

Cash and equivalents (AUD Mn)

13.614.516.3

Trade and other receivables (AUD Mn)

—21.718.2

Inventories (AUD Mn)

—9.311.3

Total current assets (AUD Mn)

—51.650.3

Goodwill (AUD Mn)

—21.421.4

Capitalised development & other intangibles (AUD Mn)

—6.86.8

Total assets (AUD Mn)

—91.188.5

Short-term borrowings (AUD Mn)

—0.160.14

Long-term borrowings (AUD Mn)

000

Lease liabilities, total (AUD Mn)

—3.73.8

Contingent consideration liabilities (AUD Mn)

—12.82.5

Contract liabilities (AUD Mn)

—6.43.8

Total liabilities (AUD Mn)

—39.326.4

Total equity (AUD Mn)

44.451.762.1

Net cash excl. leases (AUD Mn)

—14.316.1

Net cash incl. leases (AUD Mn)

—10.612.3

Working capital, current assets less current liabilities (AUD Mn)

—18.426.8

NTA per share incl. ROU (A cents)

—5.428.24

“—” = not publicly disclosed.

Cash Flow and Margin Analysis (%)

MetricFY2025FY2026

Operating cash flow (AUD Mn)

13.412.5

Capex — plant & equipment (AUD Mn)

2.80.8

Capitalised development / intangibles (AUD Mn)

2.02.0

Free cash flow, OCF less capex and capitalised development (AUD Mn)

8.79.7

Lease principal payments (AUD Mn)

0.81.4

FCF after leases (AUD Mn)

7.98.3

Acquisitions net of cash acquired (AUD Mn)

6.70

Contingent consideration paid (AUD Mn)

0.86.0

Dividends paid (AUD Mn)

00

Buybacks (AUD Mn)

00

Net change in cash (AUD Mn)

0.72.3

OCF / EBITDA conversion (%)

10384

Returns & Leverage Ratios (%) and Financial Ratios (x)

RatioFY2025FY2026

ROE, NPAT / average equity (%)

12.315.8

ROA, NPAT / average assets (%)

—10.0

ROIC, NOPAT / invested capital (%)

not calculated

17.0

Current ratio (x)

1.562.14

Debt / equity incl. leases (%)

7.56.4

Net debt / EBITDA (x)

-0.8-0.8

Interest coverage, EBIT / finance costs (x)

44.427.9

Asset turnover, revenue / average assets (x)

not calculable

1.05

Days sales outstanding (days)

9770

Days inventory outstanding (days)

8794

Days payables outstanding (days)

116109

Cash conversion cycle (days)

6855

Region Overview

RegionEquipmentInstallationSoftware/SMATotal

Australia/New Zealand

26.918.67.352.8

North America

19.49.41.630.4

Europe

2.21.40.84.4

Asia

3.31.71.76.7

Total

51.931.011.494.2

Australia/New Zealand

21.314.02.938.2

North America

15.47.54.527.4

Europe

2.61.70.65.0

Asia

6.92.41.510.8

Total

46.325.69.681.4

Region revenue (AUD Mn)

Region revenue (AUD Mn)FY2025FY2026

Australia/New Zealand

38.252.8

North America

27.430.4

Asia

10.86.7

Europe

5.04.4

Region revenue growth (%)

FY2026

—

Australia/New Zealand

38.1—

North America

11.0—

Asia

-38.1—

Europe

-12.4—

Region share of revenue (%)

FY2025

FY2026

Australia/New Zealand

4756

North America

3432

Asia

137

Europe

65

Revenue by Region

UCR by region (AUD Mn)Feb-2026Aug-2026

North America

24.224.5

Australia/New Zealand

16.216.7

Asia

4.88.0

Europe

2.11.9

Total

47.251.2

Year-end share price (AUD)

Year-end share price (AUD)FY2022FY2023FY2024FY2025FY2026

Closing price at 30 June

0.100.170.180.290.25

Share Price & Returns

PeriodApproximate performanceBasis

1-year (Oct 2025 → Oct 2026)

Approx. -35% to -40% (from c. A$0.41–0.44 around the Oct 2025 AGM to c. A$0.25–0.27)

InvestSMART announcement price records

3-year (Oct 2023 → Oct 2026)

Approx. +25% to +45% (FY24 trading range A$0.17–0.22)

StockLight 52-week ranges; InvestSMART

vs S&P/ASX 200 (1-year)

-19.3% relative underperformance (as reported)

Market Index

52-week range

Approx. A$0.22–0.445 (aggregator data; verify live)

Yahoo Finance (FR); InvestSMART

Valuation Snapshot

MetricValueBasis

Share price

c. A$0.25

InvestSMART (Oct 2026)

Shares on issue

c. 375m

Analyst estimate from Simply Wall St ownership breakdown and FY26 EPS denominator (c. 372.5m weighted)

Market capitalisation

c. A$94m

InvestSMART

Enterprise value (market cap – cash + borrowings + leases)

c. A$82m

Analyst-calculated from 30 Jun 2026 balance sheet

P/E (FY26 basic EPS 2.418c)

c. 10.3x

Analyst-calculated

P/E on underlying NPAT (A$8.1m)

c. 11.6x

Analyst-calculated

EV/EBITDA (FY26 A$14.8m)

c. 5.5x

Analyst-calculated

EV/Sales (FY26)

c. 0.87x

Analyst-calculated

P/B (net assets A$62.1m)

c. 1.5x

Analyst-calculated

FCF yield (FCF after leases A$8.3m)

c. 8.8%

Analyst-calculated

Dividends paid per share (A cents)

Dividends paid per share (A cents)FY2022FY2023FY2024FY2025FY2026

Dividend

00.475000

Capital Markets

ItemStatus

Buyback authorisation

None disclosed

Moody's / S&P / Fitch ratings

Not rated

Bank debt

None; short-term borrowings A$0.14m

Lease liabilities

A$1.1m current; A$2.7m non-current (30 Jun 2026)

Deferred consideration maturities

G&S earn-out A$2.5m due March 2027; MCS earn-out est. A$0.64m after FY27 audit

Potential dilution

8,198,754 performance rights on issue (2,730,877 vested on FY26 accounts)

Analyst Conclusions

Management guidance

Austco has not issued quantitative FY27 guidance. It enters FY27 with a "healthy sales pipeline", momentum across all regions and A$51.2m of UCR at 17 August 2026, up 13% since 30 June 2026 on genuine new order intake (FY26 Investor Presentation and Directors' Report). Management expects integration efficiencies and lower input costs to continue supporting gross margin in FY27, and operating leverage as acquired cost bases annualise. Incremental FY27 contributions are visible from MCS (c. A$1.88m net revenue and A$0.82m EBITDA on a full-year basis, less a partial first year), the Jurong SMA (A$4.2m over ten years, c. A$0.3m in FY27) and the Pulse Mobile rollout.

Consensus expectations

Consensus estimates are not publicly disclosed in sources reviewed. The company's 10–14% organic growth target (stated October 2025) is the best available management anchor.

Bull case

  1. Recurring revenue inflection. Software/SMA growth accelerated to 19% in FY26, with 2H revenue 28% above 1H (A$6.4m versus A$5.0m), before the Jurong SMA and full Pulse Mobile deployment. UCR includes A$12.6m of SMA and software. If recurring revenue compounds at 15–20% while project revenue grows high-single digits, mix shift could lift EBITDA margins towards 18–20%.

  2. Cheap, cash-generative and debt-free. At c. 5.5x EV/EBITDA and c. 9% FCF yield with net cash, the market prices Austco as an ex-growth hardware installer despite a 27% four-year revenue CAGR and ROIC near 17%.

  3. Proven, repeatable M&A. Four deals at 3.5x EBITDA, funded internally, give a self-funding growth engine; national ANZ coverage is now in place and the formula could be exported.

Bear case

  1. Underlying earnings have stalled. Underlying NPAT was flat at A$8.1m in FY25 and FY26; overheads grew 24% versus 15.8% revenue growth, and 2H26 revenue grew only 3.4%.

  2. Order book not growing. Reported UCR fell from A$55.8m (Jul 2025) to A$51.2m (Aug 2026); even on a constant-currency basis it rose only 1% over 12 months — inconsistent with double-digit organic growth.

  3. Structural mix dilution and scale disadvantage. Recurring revenue fell from 20% of revenue (FY23) to 12% (FY26) as installation-heavy acquisitions were added; R&D intensity has fallen to 5.1% while competitors with vastly greater resources invest in AI-enabled clinical communications.

Key catalysts and monitorables (next 12 months)

TimingCatalyst / monitorableWhat to watch
Late Oct 20262026 AGM and Q1 FY27 trading updateQ1 revenue growth, UCR trajectory, any FY27 guidance
Calendar 2026Pulse Mobile rollout across ~180 US hospitalsDeployment progress, recognised software/SMA revenue, follow-on US contracts
From 1 Oct 2026Jurong ten-year SMA commencementRecurring revenue build; replication with other installed-base customers
FY27MCS integrationAccretion versus A$0.82m EBITDA target; earn-out estimate
Feb 20271H27 resultsOverhead growth versus revenue; EBITDA margin; software/SMA share
March 2027G&S earn-out payment (A$2.5m)Cash outflow; signal of G&S performance
By c. Mar 2027Einstein Tacera retrofit deliveriesLatin American follow-on wins
OngoingUS tariff regime and AUD/USDGross margin and UCR translation
OngoingFurther acquisitionsDiscipline on 3.5x multiple; geography of next deal
OngoingAsia/Europe project conversionAsia UCR of A$8.0m converting to revenue

Analyst verdict

Austco Healthcare is a well-run, conservatively financed niche operator whose recent history divides into two chapters. The first, from FY22 to FY25, was a transformation: revenue more than doubled, EBITDA margins expanded from below 14% to 16%, and a disciplined reseller roll-up converted channel partners into a direct ANZ sales and installation platform at uniformly low multiples, funded entirely from cash flow. The second chapter, which began in the second half of FY26, is a test of quality. Headline numbers remain records — A$94.2m revenue, A$14.8m EBITDA, A$9.0m NPAT — but underlying NPAT has been flat for two years, overheads are outrunning revenue, the second half barely grew, and the order book is no larger in constant currency than it was a year earlier. The market has noticed: the shares have roughly halved from their October 2025 peak and now trade at about 5.5x EV/EBITDA and 10x earnings, with net cash.

At that valuation, investors are no longer paying for growth; they are being paid to wait for evidence that the platform strategy is working. The evidence to look for is specific and measurable within twelve months: Pulse Mobile revenue recognised from the 180-hospital US rollout, the Jurong SMA replicated elsewhere in the installed base, software and SMA rising above 13–14% of revenue, and overhead growth falling back below revenue growth as acquired cost bases mature. If those markers appear, Austco's combination of a 5,000-facility installed base, a debt-free balance sheet and a repeatable acquisition engine argues for a materially higher multiple. If they do not, Austco risks being valued as what its revenue mix increasingly resembles — a competent regional installer of hardware, exposed to hospital capital cycles and outscaled by global rivals. On balance, the risk-reward is asymmetric to the upside at current prices, but the thesis is execution-dependent and catalyst-driven rather than self-evident, and position sizing should reflect micro-cap liquidity and project lumpiness.


Analyst-calculated figures are identified as such. Market data (price, market capitalisation, trailing returns) are approximate as of early October 2026 and should be refreshed from a live source.

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Executive Leadership

Executive Leadership Team

NameTitleTenurePrior rolesEducationFY26 total remuneration (AUD)

Clayton Astles

Managing Director / CEO and Executive Director

CEO since July 2015; with Austco since c. 2008

President, Austco Marketing & Services (USA); over 20 years' healthcare technology leadership

Diploma in Electronics Engineering

967,004 (salary 560,489; cash bonus 221,282; other 56,707; leave accrual 29,237; performance rights 99,289). Base fixed at US$380,000 since 2015

Brendan Maher

CFO, COO ANZ and Company Secretary

Company Secretary since October 2018

CFO of Adslot; Company Secretary of Skilled Group and Adslot; Arthur Andersen; National Westminster Bank

Chartered Accountant (CA ANZ); GAICD

540,274 (salary 363,837; bonus 80,000; leave 8,695; rights 57,742; super 30,000)

Andrew Hall

Chief Commercial Officer

———

Not a KMP; not disclosed

Matthew Pearson

Investor Relations

————

“—” = not publicly disclosed.

Board of Directors

NameRoleAppointedIndependenceCommitteesBackgroundFY26 fees (AUD)

Graeme Billings

Non-Executive Chairman

October 2015

Independent (assessed)

Chair, Audit & Risk Management Committee

Chartered Accountant since 1980; 34 years at PwC (former head of Melbourne assurance practice); former Chair of Amotiv Ltd (to Oct 2025) and NED of Clover Corporation (to Nov 2025)

111,251

Brett Burns

Non-Executive Director

October 2015

Board assesses as independent; note related-party legal (A$67k) and IR (A$60k via Pont Equity) fees

Chair, Nomination & Remuneration Committee

Managing Partner, CBW Partners (corporate law); former Company Secretary and General Counsel of an ASX top-20 company; former ASIC regulator; GAICD

86,500

Anthony Glenning

Non-Executive Director

September 2018

Independent

Member of both committees

Founder of Tonic Systems (sold to Google 2007); Starfish Ventures Investment Director 2010–2018; Fund Advisor, Skalata Ventures; NED of Pro Medicus and Iress; BEng (Elec), BCompSc (Melbourne), MSEE (Stanford)

79,000

Ann Larkins

Non-Executive Director

—

Independent

Member of both committees

Executive Director and CIO, Australian Red Cross Lifeblood; former Executive Director/CIO roles at Barwon Health and Alfred Health; critical care nursing background; Master of Business Technology (UNSW); Certified Healthcare CIO (CHIME); GAICD

79,000

Clayton Astles

Executive Director

July 2015

Not independent

Attends committees

See above

—

Board & Management Changes

DateChangeContext

FY25 (c. early 2025)

Ann Larkins joins the Board

Adds health-IT and clinical expertise

October 2025

Graeme Billings steps down from Amotiv board

Reduces external commitments

November 2025

Graeme Billings steps down from Clover Corporation board

As above

FY27

Formal succession planning programme being rolled out

Disclosed as a mitigation of key-person risk (FY26 Material Business Risks)

Major Shareholders

HolderSharesStake (%)Date of last noticeSource

Asia Pac Technology Pty Ltd

54,777,79814.62

30 Sep 2025

Market Index (substantial holder notices)

Australian Ethical Investment Ltd

51,201,16114.06

22 Aug 2025 (reduced from 15.59%)

Market Index; TipRanks

Clayton Astles (CEO)

4,163,035 plus 2,131,874 performance rights

c. 1.1

30 Jun 2026

FY26 Remuneration Report

Brendan Maher (CFO)

2,427,162

c. 0.6

30 Jun 2026

FY26 Remuneration Report

Brett Burns

1,497,504

c. 0.4

30 Jun 2026

FY26 Remuneration Report

Anthony Glenning

1,058,870

c. 0.3

30 Jun 2026

FY26 Remuneration Report

Graeme Billings

530,776

c. 0.1

30 Jun 2026

FY26 Remuneration Report

Competitive Landscape

Key Competitors

CompetitorParent / ownershipPrimary overlapGeography of overlapRelative positioning vs AustcoRevenue (comparable segment)

Rauland (Responder nurse call)

AMETEK Inc.

Nurse call, clinical workflow

North America, ANZ, Middle East

Market leader in US nurse call; far larger scale

Not separately disclosed by parent

Hillrom (Voalte, NaviCare nurse call)

Baxter International

Nurse call, mobile communications, care coordination

North America, global

Integrated with beds/devices; much broader portfolio

Not separately disclosed at product level

Ascom

Ascom Holding AG (SIX-listed)

Nurse call (telligence, teleCARE), mobile messaging, alarm management

Europe, ANZ, North America

Strongest European incumbent; broader mobile workflow

—

Vocera

Stryker Corporation

Clinical communications, wearable badges, mobile messaging

North America, ANZ, UK

Leader in mobile clinical comms; overlaps with Pulse Mobile

Not separately disclosed by parent

Jeron Electronic Systems

Private

Nurse call (Provider)

North America

Mid-market US specialist

—

Spok

Spok Holdings (NASDAQ: SPOK)

Clinical communications, paging, alarm management

North America

Software-centric; complements or substitutes Pulse

—

Cornell Communications

Private

Nurse call (aged care focus)

North America

Lower-cost aged-care competitor

—

TekTone

Private

Nurse call

North America

Value-segment competitor

—

Critical Alert

Private

Nurse call and clinical workflow

North America

Software-led US competitor

—

Courtney Thorne / Static Systems / Intercall

Private UK specialists

Nurse call

UK

Local incumbents in UK NHS and care homes

—

Local integrators and Ascom/Rauland resellers

Various

Installation and low-voltage integration

ANZ

Compete for installation scopes Austco now self-performs

—

“—” = not publicly disclosed.

Competitor Detail

MetricAustco (FY26)

Revenue

A$94.2m

Revenue growth

15.8%

Gross margin

53.4%

EBITDA margin

15.8%

R&D intensity

5.1%

Recent Developments

A 2026 AGM (typically late October) and Q1 FY27 trading update are expected but had not been released as at the research cut-off.*

Company Snapshot

$60.8M

Revenue

271

Employees

1986

Founded

Port Melbourne, Australia

Headquarters

SWOT Analysis

Strengths

  • Consistent profitable growth: revenue CAGR of 27.3% (FY22–FY26) and NPAT rising from A$2.3m to A$9.0m (FY26 Remuneration Report five-year table).
  • Debt-free balance sheet: A$16.3m cash, no material borrowings, net assets A$62.1m at 30 Jun 2026 (FY26 Appendix 4E).
  • Stable gross margins: 52.0–53.4% over FY24–FY26 despite a mix shift to installation (FY26 Directors' Report).
  • Proven acquisition formula: four deals at 3.5x EBITDA, all funded from cash flow; Amentco earn-out outperformed (A$8.4m settled versus A$5.9m recognised) (FY26 M&A scorecard).
  • Installed base: >5,000 facilities in >60 countries provides annuity potential (FY26 Investor Presentation).
  • Order-book visibility: UCR of A$51.2m (17 Aug 2026), equal to about 54% of FY26 revenue, of which A$12.6m is software/SMA (FY26 Investor Presentation).
  • Strong cash generation: FY26 operating cash flow A$12.5m funded a A$6.0m earn-out while cash still rose (FY26 cash flow statement).

Weaknesses

  • Flat underlying earnings: underlying NPAT A$8.1m in both FY25 and FY26 (FY26 Investor Presentation).
  • Low recurring share: software/SMA only 12.0% of revenue, down from 20.2% in FY23 as acquisitions added installation revenue (FY23 and FY26 releases).
  • Overhead creep: overheads rose to 42.4% of revenue from 40.0%, up 24% YoY (FY26 Directors' Report).
  • 2H26 deceleration: 2H revenue up only 3.4% after a 30.7% 1H rise (FY26 Directors' Report).
  • Falling R&D intensity: gross R&D flat at A$4.8m; intensity down from 7.7% (FY24) to 5.1% (FY26) (FY26 Note 4).
  • Stagnant Australian organic base: Australian external revenue up only 1.3% to A$32.0m in FY26 (FY26 Note 5).
  • Statutory earnings noise: contingent-consideration remeasurements of -A$2.2m (FY25) and +A$0.9m (FY26), and a A$1.4m FY24 tax credit, obscure trends.

Opportunities

  • US Pulse Mobile rollout: ~180 hospitals of the largest US customer during calendar 2026 (FY26 Trading Update).
  • Base monetisation via long SMAs: the ten-year A$4.2m Jurong SMA (from Oct 2026) is a replicable template (ASX, 24 Jul 2026).
  • Latin America: Einstein (A$1.85m phase one) and Angeles Health (A$3.4m) provide flagship references (FY26 Investor Presentation; Halo feed).
  • AI layer: predictive clinical intelligence and predictive maintenance could deepen SMA value (FY26 AI roadmap).
  • Further reseller roll-ups: MCS completes national ANZ coverage; similar formula could extend to other markets (FY26 M&A scorecard).
  • Operating leverage: acquired cost bases have now annualised; management expects margin support in FY27 from integration and lower input costs (FY26 Directors' Report).
  • Asia recovery: Asia UCR rose to A$8.0m from A$4.8m between Feb and Aug 2026 (1H26 release; FY26 Presentation).

Threats

  • Scale disadvantage versus AMETEK, Baxter, Stryker and Ascom in R&D and enterprise sales reach.
  • Tariffs: US tariffs on China-sourced inputs affect costs and customer timing (FY26 Material Business Risks).
  • FX translation: ~80% of UCR in foreign currencies; A$2.6m FX translation loss in FY26 OCI (FY26 Directors' Report).
  • Hospital capital-budget pressure: management cited slower construction programmes and harder capital budgeting in FY26 (FY26 Investor Presentation).
  • Cyber risk: connected clinical systems are attack targets; Essential Eight uplift still in progress (FY26 Material Business Risks).
  • Single-source components: disruption could delay projects and compress margins (FY26 Material Business Risks).
  • Key-person dependency: small senior team; formal succession programme only being rolled out in FY27 (FY26 Material Business Risks).

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Key Developments

DateEventSignificance
1 Apr 2025Austco secures largest SMA contract in company history Halo announcement feedValidates recurring-revenue strategy
9 Apr 2025Binding term sheet to acquire G&S Technologies (NZ) at 3.5x EBITDA ASX (via InvestorPA)Largest acquisition to date; NZ entry
Mid-Apr 2025A$3.4m contract with Angeles Health (Mexico) Halo; MarketBeatLatin American expansion
Apr–May 2025Agreement signed with a leading US healthcare provider Halo announcement feedUS pipeline building
13 May 2025A$2.1m contract for Toronto Western Hospital project MarketBeat news feedCanadian public hospital reference
May 2025G&S Technologies acquisition completed (NZ$7.97m upfront) TechPartner NewsAdds ~NZ$23m revenue base
Jul 2025Trading update and guidance upgrade; record June 2025 revenue of A$13.2m (unaudited); UCR A$55.8m HotCopper thread cited by StrawmanMomentum into FY26
4 Jul 2025Australian Ethical sells 5.56m shares; stake falls from 15.59% to 14.06% Simply Wall St; TipRanksMajor holder trimming
26 Aug 2025FY25 results: revenue +40% to A$81.4m; EBITDA +62% to A$13.0m; NPAT A$5.9m FY25 Results ReleaseRecord result; NPAT down on contingent consideration
17 Sep 20252025 Annual Report released InvestSMART announcements listStatutory filing
19–23 Sep 2025Proposed issue of securities and cleansing notice InvestSMART announcements listShare issuance (consistent with scrip settlement of earn-out obligations)
30 Sep 2025John Bennetts sells 2.12m shares at up to A$0.37; Asia Pac Technology substantial holding notice (14.62%) Simply Wall St; Market IndexRegister changes
13 Oct 2025Investor presentation released InvestSMARTInvestor outreach
16 Oct 2025Issue of performance rights to senior management FY26 Remuneration ReportLTI grant at 44.0c share price
29 Oct 2025Q1 FY26 trading update: revenue +51% to A$23.2m; EBITDA A$4.2m (18.1% margin); UCR A$54.6m; 10–14% organic growth target; AGM held (remuneration report 99.1% support) Q1 FY26 Trading Update; AGM resultsStrong start to FY26; share price near 12-month high (c. A$0.41–0.44)
6 Jan 2026Notification of cessation of securities InvestSMARTLapse/cancellation of options or rights
18 Feb 20261H26 results: revenue +30.7% to A$48.2m; EBITDA +60.1% to A$8.3m; NPAT +61.7% to A$4.7m; cash A$15.2m; UCR A$47.2m 1H26 Results ReleaseRecord half; UCR decline from October flagged
4 & 11 Mar 2026Director interest notices (Burns, Astles) InvestSMARTInsider transactions
1 Jun 2026FY26 trading update: revenue A$90–95m, EBITDA A$14.0–14.6m, NPAT A$9.0–9.4m; Pulse Mobile rollout across ~180 US hospitals; wins in NZ (NZ$1.1m), Warrnambool (A$1.1m), North York General (A$0.9m) FY26 Trading Update; KalkineImplied soft 2H; share price fell sharply
24 Jul 2026Ten-year A$4.2m Tacera maintenance contract at Jurong Health Complex, Singapore ASX (via InvestSMART)Largest-duration annuity; recurring revenue anchor
10 Aug 2026Announcement of MCS acquisition (South Australia) ASX (10 Aug 2026)Fourth reseller roll-up
13 Aug 2026MCS acquisition completed FY26 Directors' ReportPost-balance-date event
27 Aug 2026FY26 results: revenue A$94.2m (+15.8%), EBITDA A$14.8m (+14%), NPAT A$9.0m (+51.8%), underlying NPAT flat at A$8.1m; no dividend; UCR A$51.2m FY26 Appendix 4ERecord, but underlying earnings flat
27 Aug 2026Hospital Israelita Albert Einstein (Brazil) Tacera retrofit disclosed: A$1.85m phase-one POs, deliveries to c. March 2027 FY26 Investor PresentationFlagship Latin American reference
27 Aug 2026Appendix 4G and Corporate Governance Statement filed FilingReader filing listGovernance disclosure
Mid-Sep 20262026 Annual Report (scheduled 16 Sep 2026 per data providers) Market Index; InvestSMART calendarStatutory filing; AGM notice expected to follow
1 Oct 2026Jurong ten-year SMA commences ASX (24 Jul 2026)Recurring revenue begins

Financial Performance

Explore key financial metrics, segmented revenue, balance sheet health, and performance trends.

Revenue

4 charts
Income Statement: Revenue & Gross Profit: Revenue rose from AUD 58.2 Mn in FY2024 to AUD 94.2 Mn in FY2026.
Austco Healthcare Limited — Income Statement: Revenue & Gross Profit
Series (AUD Mn)FY2024FY2025FY2026
Revenue58.281.494.2
Gross profit30.742.450.3

Unlock Company Financials

Unlock this company profile to view its financial data.

View Subscription Plans

Unlock Company Contacts

Connect with Key Decision-Makers

Access verified employee contacts and decision-maker information from this company to support your sales, lead generation, and business development efforts.